ArticleMedicine2026
Prevalence and risk factors of pulmonary hypertension in maintenance hemodialysis patients based on echocardiography.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to use echocardiography to explore the prevalence of pulmonary hypertension (PH) in maintenance hemodialysis patients with different vascular accesses and analyze the risk factors for combined PH. A cross-sectional analysis was conducted on 757 end-stage renal disease patients receiving maintenance hemodialysis. Patients were categorized by the type of access used during echocardiographic examination: central vein catheter (CVC) and autogenous arteriovenous fistula (AVF)/arteriovenous graft (AVG). They were further grouped by tricuspid regurgitation velocity to determine PH prevalence. Multinomial logistic regression analysis evaluated the relevant risk factors. (1) Among maintenance hemodialysis patients, 39.23% had a moderate to high likelihood of PH; 248 patients (32.76%) had diastolic dysfunction, 184 patients (24.31%) had pericardial effusion, 381 patients (50.33%) had left ventricular hypertrophy, and 268 patients (35.40%) had aortic regurgitation. Diastolic dysfunction may indicate early heart failure and PH progression. (2) In the CVC group, 62 patients (24.22%) had moderate PH, and 9 (3.52%) had severe PH. Left atrium diameter (OR = 1.086, 95% CI 1.024-1.151, P = .006 and OR = 1.123, 95% CI 1.001-1.260, P = .048) showed statistical significance in moderate and severe PH groups, respectively. Right ventricular end-systolic diameter (RVDS) (OR = 1.519, 95% CI 1.151-2.005, P = .003) was significant in the severe PH group. (3) In the AVF/AVG group, 158 patients (31.54%) had moderate PH, and 68 (13.57%) had severe PH. RVDS (OR = 1.183, 95% CI 1.078-1.298, P < .001 and OR = 1.607, 95% CI 1.413-1.829, P < .001) showed significance in moderate and severe PH groups. Left atrium diameter (OR = 1.060, 95% CI 1.004-1.120, P = .035) showed significance in the severe PH group. The incidence of PH in maintenance hemodialysis patients is high and is closely related to volume overload, vascular access type, and right ventricular enlargement. For patients with right ventricular dilation (e.g., RVDS > 25 mm) or moderate to severe PH, careful evaluation of the benefit-risk ratio for AVF/AVG should be conducted. In selected high-risk cases, alternative access such as CVC may be appropriate. Prospective studies are needed to further compare the long-term effects of different access types on PH progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.